• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Rogers Corporation

Rogers Corporation

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Rogers Corporation Reports First Quarter 2017 Results

    Rogers Corporation Reports First Quarter 2017 Results

  2. Genentech to Present New Data on Personalized Medicines and Cancer Immunotherapies at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting

    Genentech to Present New Data on Personalized Medicines and Cancer Immunotherapies at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting

  3. Genentech Provides Update on Phase III Study of TECENTRIQ (Atezolizumab) in People with Previously Treated Advanced Bladder Cancer

    Genentech Provides Update on Phase III Study of TECENTRIQ (Atezolizumab) in People with Previously Treated Advanced Bladder Cancer

  4. Global Medical Foam Market to Reach $31 Billion by 2025 - Increase in Reticulated Polyurethane Foams in the Medical Industry - Research and Markets

    Global Medical Foam Market to Reach $31 Billion by 2025 - Increase in Reticulated Polyurethane Foams in the Medical Industry - Research and Markets

  5. Global Flexible Foams Market to Grow at a CAGR of 5.78% by 2021: Growth in Bedding & Furniture Industry Driven by Expanding Population - Research and Markets

    Global Flexible Foams Market to Grow at a CAGR of 5.78% by 2021: Growth in Bedding & Furniture Industry Driven by Expanding Population - Research and Markets

  6. ASUS Republic of Gamers Brings NRG eSports Closer to Gaming Domination

    ASUS Republic of Gamers Brings NRG eSports Closer to Gaming Domination

  7. Roche Revenue Up 4% at CHF12.94 Billion on Strong Sales

    Roche Revenue Up 4% at CHF12.94 Billion on Strong Sales

  8. UPDATE: These are the only 9 stocks Morningstar is fully bullish on

    UPDATE: These are the only 9 stocks Morningstar is fully bullish on

  9. New Data at AAN Reinforce Clinical Benefit of Genentech’s OCREVUS (Ocrelizumab) for Relapsing and Primary Progressive Multiple Sclerosis

    New Data at AAN Reinforce Clinical Benefit of Genentech’s OCREVUS (Ocrelizumab) for Relapsing and Primary Progressive Multiple Sclerosis

  10. One-Stop Shopping for Exposure to International Stocks

    This iShares’ ETF has appeal, but investors don't have to go much further afield to find more-compelling options.

12

©2017 Morningstar Advisor. All right reserved.